60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
11 déc. 2024 08h56 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
28 août 2024 14h48 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days.
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
14 août 2024 11h01 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
06 août 2024 09h26 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price requirement.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
02 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14 mars 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma advises of expected FDA response a month later than anticipated. Prepares for June 1, 2024, start of trial of tafenoquine for babesiosis.